Literature DB >> 22885417

2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis.

Ivânio Alves Pereira1, Licia Maria Henrique da Mota, Boris Afonso Cruz, Claiton Viegas Brenol, Lucila Stange Rezende Fronza, Manoel Barros Bertolo, Max Victor Carioca de Freitas, Nilzio Antônio da Silva, Paulo Louzada-Junior, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima, Geraldo da Rocha Castelar Pinheiro.   

Abstract

OBJECTIVE: To elaborate recommendations of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology (SBR) to manage comorbidities in rheumatoid arthritis (RA).
METHODS: To review the literature and the opinions of the SBR RA Committee experts. RECOMMENDATIONS: 1) Early diagnosis and proper treatment of comorbidities are recommended; 2) The specific treatment of RA should be adapted to the presence of comorbidities; 3) Angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers are preferred to treat systemic arterial hypertension; 4) In patients diagnosed with rheumatoid arthritis and diabetes mellitus, the continuous use of a high cumulative dose of corticoids should be avoided; 5) Statins should be used to maintain LDL cholesterol levels under 100 mg/dL and the atherosclerotic index lower than 3.5 in patients with RA who have other comorbidities; 6) Metabolic syndrome should be treated; 7) Performing non-invasive tests to investigate subclinical atherosclerosis is recommended; 8) Greater surveillance for the early diagnosis of occult malignancy is recommended; 9) Preventive measures of venous thrombosis are suggested; 10) Bone densitometry is recommended in RA patients over the age of 50 years and in younger patients on corticoid therapy at a dose greater than 7.5 mg for over three months; 11) Patients with RA and osteoporosis should be instructed to avoid falls, to increase their dietary calcium intake and sun exposure, and to exercise; 12) Calcium and vitamin D supplementation is suggested. Bisphosphonates are suggested for patients with T score < -2.5 on bone densitometry; 13) A multidisciplinary team, with the active participation of a rheumatologist, is recommended to treat comorbidities.

Entities:  

Mesh:

Year:  2012        PMID: 22885417

Source DB:  PubMed          Journal:  Rev Bras Reumatol        ISSN: 0482-5004


  5 in total

1.  Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis.

Authors:  JaeJin An; Eric Nyarko; Mohammad Adam Hamad
Journal:  Clin Rheumatol       Date:  2019-05-27       Impact factor: 2.980

Review 2.  Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis.

Authors:  Estíbaliz Loza; Cristina Lajas; Jose Luis Andreu; Alejandro Balsa; Isidoro González-Álvaro; Oscar Illera; Juan Ángel Jover; Isabel Mateo; Javier Orte; Javier Rivera; José Manuel Rodríguez Heredia; Fredeswinda Romero; Juan Antonio Martínez-López; Ana María Ortiz; Esther Toledano; Virginia Villaverde; Loreto Carmona; Santos Castañeda
Journal:  Rheumatol Int       Date:  2014-12-28       Impact factor: 2.631

3.  Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.

Authors:  Andrea B V Lomonte; Sebastião C Radominski; Flora M D Marcolino; Claiton V Brenol; Cristiano A F Zerbini; Erika G García; Ermeg L Akylbekova; Ricardo Rojo; Dario Ponce de Leon
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

4.  Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study.

Authors:  Gustavo Nogueira Schincariol Vicente; Ivânio Alves Pereira; Gláucio Ricardo Werner de Castro; Licia Maria Henrique da Mota; Ana Paula Carnieletto; Dhara Giovanna Santin de Souza; Fabiana Oenning da Gama; Ana Beatriz Vargas Santos; Cleandro Pires de Albuquerque; Manoel Barros Bértolo; Paulo Louzada Júnior; Rina Dalva Neubarth Giorgi; Sebastião Cezar Radominski; Maria Fernanda Brandão Resende Guimarães; Karina Rossi Bonfiglioli; Maria de Fátima Lobato da Cunha Sauma; Claiton Viegas Brenol; Geraldo da Rocha Castelar Pinheiro
Journal:  Adv Rheumatol       Date:  2021-06-25

5.  Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN-γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients.

Authors:  Pablo R G Cardoso; Katherine A Matias; Andrea T Dantas; Claudia D L Marques; Michelly C Pereira; Angela L B P Duarte; Moacyr Jesus Barreto de Melo Rego; Ivan da Rocha Pitta; Maira Galdino da Rocha Pitta
Journal:  Open Rheumatol J       Date:  2018-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.